106 related articles for article (PubMed ID: 35245914)
41. Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables.
Rudolph KE; Díaz I; Hejazi NS; van der Laan MJ; Luo SX; Shulman M; Campbell A; Rotrosen J; Nunes EV
Addiction; 2021 Aug; 116(8):2094-2103. PubMed ID: 33340181
[TBL] [Abstract][Full Text] [Related]
42. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review.
Shirk SD; Ameral V; Kraus SW; Houchins J; Kelly M; Pugh K; Reilly E; Desai N
J Dual Diagn; 2021; 17(3):207-215. PubMed ID: 34176448
[TBL] [Abstract][Full Text] [Related]
43. Choice of extended release medication for OUD in young adults (buprenorphine or naltrexone): A pilot enhancement of the Youth Opioid Recovery Support (YORS) intervention.
Wenzel K; Selby V; Wildberger J; Lavorato L; Thomas J; Fishman M
J Subst Abuse Treat; 2021 Jun; 125():108306. PubMed ID: 34016297
[TBL] [Abstract][Full Text] [Related]
44. Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report.
Harris M; Johnson S; Mackin S; Saitz R; Walley AY; Taylor JL
J Addict Med; 2020; 14(4):e136-e138. PubMed ID: 32433364
[TBL] [Abstract][Full Text] [Related]
45. Factors associated with non-adherence to Buprenorphine-naloxone among opioid dependent African-Americans: A retrospective chart review.
Kumari S; Manalai P; Leong S; Wooditch A; Malik M; Lawson WB
Am J Addict; 2016 Mar; 25(2):110-7. PubMed ID: 26749158
[TBL] [Abstract][Full Text] [Related]
46. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
[TBL] [Abstract][Full Text] [Related]
47. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
[TBL] [Abstract][Full Text] [Related]
48. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care.
Egan JE; Netherland J; Gass J; Finkelstein R; Weiss L;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S46-53. PubMed ID: 21317594
[TBL] [Abstract][Full Text] [Related]
49. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
Piske M; Zhou H; Min JE; Hongdilokkul N; Pearce LA; Homayra F; Socias ME; McGowan G; Nosyk B
Addiction; 2020 Aug; 115(8):1482-1493. PubMed ID: 31899565
[TBL] [Abstract][Full Text] [Related]
50. Association between Participation in Counseling and Retention in a Buprenorphine-Assisted Treatment Program for People Experiencing Homelessness with Opioid Use Disorder.
Berry ARW; Finlayson TL; Mellis LM; Urada LA
Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769591
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial.
Polsky D; Glick HA; Yang J; Subramaniam GA; Poole SA; Woody GE
Addiction; 2010 Sep; 105(9):1616-24. PubMed ID: 20626379
[TBL] [Abstract][Full Text] [Related]
52. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.
Ling W; Amass L; Shoptaw S; Annon JJ; Hillhouse M; Babcock D; Brigham G; Harrer J; Reid M; Muir J; Buchan B; Orr D; Woody G; Krejci J; Ziedonis D;
Addiction; 2005 Aug; 100(8):1090-100. PubMed ID: 16042639
[TBL] [Abstract][Full Text] [Related]
53. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations.
Stancliff S; Joseph H; Fong C; Furst T; Comer SD; Roux P
J Addict Dis; 2012; 31(3):278-87. PubMed ID: 22873189
[TBL] [Abstract][Full Text] [Related]
54. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
[TBL] [Abstract][Full Text] [Related]
55. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.
Parran TV; Adelman CA; Merkin B; Pagano ME; Defranco R; Ionescu RA; Mace AG
Drug Alcohol Depend; 2010 Jan; 106(1):56-60. PubMed ID: 19717249
[TBL] [Abstract][Full Text] [Related]
56. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington.
Hood JE; Banta-Green CJ; Duchin JS; Breuner J; Dell W; Finegood B; Glick SN; Hamblin M; Holcomb S; Mosse D; Oliphant-Wells T; Shim MM
Subst Abus; 2020; 41(3):356-364. PubMed ID: 31403907
[No Abstract] [Full Text] [Related]
57. Prehospital Initiation of Buprenorphine Treatment for Opioid Use Disorder by Paramedics.
Hern HG; Goldstein D; Kalmin M; Kidane S; Shoptaw S; Tzvieli O; Herring AA
Prehosp Emerg Care; 2022; 26(6):811-817. PubMed ID: 34505820
[TBL] [Abstract][Full Text] [Related]
58. Treating homeless opioid dependent patients with buprenorphine in an office-based setting.
Alford DP; LaBelle CT; Richardson JM; O'Connell JJ; Hohl CA; Cheng DM; Samet JH
J Gen Intern Med; 2007 Feb; 22(2):171-6. PubMed ID: 17356982
[TBL] [Abstract][Full Text] [Related]
59. Buprenorphine alone or with naloxone: Which is safer?
Kelty E; Cumming C; Troeung L; Hulse G
J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
[TBL] [Abstract][Full Text] [Related]
60. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.
Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK
J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
